Table 4 Predicted conservancy of the antigenic site by using IEDB conservancy analysis [31]
Sequence | Identity % |
|---|---|
Bepipred analysis | |
VRPGNFNQ | 17.39 |
GNAAIT | 41.30 |
DKSAGHPFN | 17.39 |
SYQEQ | 17.39 |
DVDNP | 41.30 |
YPKCDRA | 100.00 |
YYVKPGGTSSGDATTAY | 17.39 |
IEDB analysis | |
DYKVQLFEKYFKY | 17.39 |
HANCVNCTDDRCVLHCANFNVLFAM | 17.39 |
KTCFGPIVRKIFVDGVPFVVSCGYHYKELGLV | 17.39 |
VSLHRHRLSLK | 17.39 |
ADPAMHI | 17.39 |
SSNAFLDLRTSCFSVAALTTG | 17.39 |
YDFVVSKG | 17.39 |
SVTLKHFFFA | 17.39 |
DYNYYSYN | 17.39 |
PTMCDIKQMLFCMEVVNKYFEI | 17.39 |
DGGCLNASEVVVNN | 17.39 |
KARVYYESM | 17.39 |
LKYAIS | 100.00 |
TVAGVSILS | 41.30 |
GATCVIGTT | 17.39 |
LKTLYKDV | 17.39 |
YPKCDRA | 100.00 |
CRIFASLILARKHGTCCTT | 17.39 |
YRLANECAQVLSEYVLCGGGYYVKPG | 17.39 |
ANSVFNILQA | 17.39 |
TANVSAL | 17.39 |
Surface accessibility prediction analysis | |
HRHRLS | 17.39 |
GNFNQDF | 41.30 |
TDYNYYSYNL | 17.39 |
ARVYYESMSYQEQD | 17.39 |
AKNRAR | 56.52 |
MTNRQYHQKML | 17.39 |
TLYKDVD | 17.39 |
WDYPKC | 100.00 |
TRDRFY | 17.39 |